OncoDNA combines advanced testing of clinically relevant cancer biomarkers (DNA, RNA and protein) from solid and liquid biopsies with a proprietary cancer treatment knowledge database to deliver one‑stop analysis and interpretation services. Its web‑based OncoKDM software processes raw NGS data to generate clinical insights such as treatment options and clinical‑trial matches for oncologists. The company also licenses its interpretation software to molecular laboratories and collaborates with biopharma on clinical‑trial design, enrollment and assessment. OncoDNA completed a €19 million Series B equity financing to support rapid international growth, accelerate software development and expand hiring. The company aims to become the European leader in oncogenomic data interpretation and to connect molecular laboratories to its advanced interpretation tools. OncoDNA is based in Gosselies, Belgium, employs 50 people across four countries, has an international network of 35 distributors covering approximately 50 countries, and collaborates with a subcontracted laboratory of about 300 collaborators. OncoDNA is a precision medicine company based in Gosselies, Belgium, that provides molecular and proteomic analyses to guide cancer treatment decisions. Led by CEO Jean-Pol Detiffe, the company supports oncologists daily in finding treatment options for advanced cancer patients. Its product suite includes OncoDEEP (DNA sequencing and protein analyses of solid biopsies), OncoDEEP&TRACE (combined solid tumour and liquid biopsy analyses), OncoTRACE (a blood-based tumor monitoring solution), and OncoSHARE (sample logistics, ordering, process follow-up, data analysis and sharing). The company closed a €7.7M equity financing round and intends to use the proceeds to further accelerate global market expansion. No revenue or user metrics were disclosed in the article.

Total raised

$29M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2020